Announced Tue, 28 Apr · 21:17 IST
Piramal Pharma FY26: Revenue Down 3%, Posts ₹326 Cr Loss on Impairment
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.7%1-day move
₹164.85
prior close
₹163.25
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.7+1.1+1.8+2.7-1.7-2.6-3.0+0.1+11.4+11.6+7.2+4.9+1.0—
Up moveDown movePending
AI summary
FY26 revenue fell 3% to ₹8,869 Cr; EBITDA dropped 28% to ₹1,135 Cr with margin compressing from 17% to 13%. CDMO revenue declined 10%, while CHG grew 3% and PCH 17%. Company reported a net loss of ₹326 Cr after a ₹196 Cr impairment on intangible assets under development. Net debt held flat at ₹4,140 Cr. Management called FY26 transitional, expecting growth in FY27 driven by CDMO order recovery, Kenalog® acquisition, and Power Brands.
Likely market impact
Impairment-driven loss and margin compression weigh on earnings, but management flags FY27 recovery on CDMO rebound and PCH growth.